CAN Stock Overview
Cann Group Limited operates in the medical cannabis industry in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.30|
|52 Week High||AU$0.92|
|52 Week Low||AU$0.28|
|1 Month Change||3.45%|
|3 Month Change||0%|
|1 Year Change||-54.55%|
|3 Year Change||-84.85%|
|5 Year Change||n/a|
|Change since IPO||-53.49%|
Recent News & Updates
Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now
The underwhelming share price performance of Cann Group Limited ( ASX:CAN ) in the past three years would have...
|CAN||AU Pharmaceuticals||AU Market|
Return vs Industry: CAN underperformed the Australian Pharmaceuticals industry which returned -12.7% over the past year.
Return vs Market: CAN underperformed the Australian Market which returned 10.2% over the past year.
|CAN Average Weekly Movement||5.8%|
|Pharmaceuticals Industry Average Movement||8.4%|
|Market Average Movement||8.4%|
|10% most volatile stocks in AU Market||15.7%|
|10% least volatile stocks in AU Market||3.7%|
Stable Share Price: CAN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CAN's weekly volatility (6%) has been stable over the past year.
About the Company
Cann Group Limited operates in the medical cannabis industry in Australia. It licenses to undertake research and to cultivate cannabis for human medicinal and research purposes. The company was founded in 2014 and is based in Bundoora, Australia.
Cann Group Fundamentals Summary
|CAN fundamental statistics|
Is CAN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CAN income statement (TTM)|
|Cost of Revenue||AU$48.00k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.072|
|Net Profit Margin||-294.39%|
How did CAN perform over the long term?See historical performance and comparison
Is Cann Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CAN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CAN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CAN is unprofitable, so we can't compare its PE Ratio to the Global Pharmaceuticals industry average.
PE vs Market: CAN is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CAN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CAN is good value based on its PB Ratio (1.1x) compared to the AU Pharmaceuticals industry average (3.2x).
How is Cann Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CAN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CAN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CAN's revenue (84.3% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: CAN's revenue (84.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CAN is forecast to be unprofitable in 3 years.
How has Cann Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CAN is currently unprofitable.
Growing Profit Margin: CAN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CAN is unprofitable, and losses have increased over the past 5 years at a rate of 45.5% per year.
Accelerating Growth: Unable to compare CAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.4%).
Return on Equity
High ROE: CAN has a negative Return on Equity (-27.32%), as it is currently unprofitable.
How is Cann Group's financial position?
Financial Position Analysis
Short Term Liabilities: CAN's short term assets (A$22.1M) exceed its short term liabilities (A$9.6M).
Long Term Liabilities: CAN's short term assets (A$22.1M) exceed its long term liabilities (A$271.0K).
Debt to Equity History and Analysis
Debt Level: CAN is debt free.
Reducing Debt: CAN has no debt compared to 5 years ago when its debt to equity ratio was 0%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CAN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CAN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.1% each year
What is Cann Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CAN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CAN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Peter Crock, B.Ag.Sci (Hons), MBA has been Chief Executive Officer at Cann Group Limited since May 23, 2016. Mr. Crock is an experienced public company senior manager with strong skills in marketing an...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD256.24K) is about average for companies of similar size in the Australian market ($USD290.68K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Experienced Management: CAN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: CAN's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CAN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.2%.
Cann Group Limited's employee growth, exchange listings and data sources
- Name: Cann Group Limited
- Ticker: CAN
- Exchange: ASX
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$104.656m
- Shares outstanding: 348.85m
- Website: https://www.canngrouplimited.com
- Cann Group Limited
- 4 Research Avenue
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/04 07:02|
|End of Day Share Price||2021/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.